Division of Genetics and Development, Toronto Western Research Institute and Krembil Neuroscience Center, University Health Network, Toronto, Ontario M5T 2S8, Canada.
J Neurosci. 2010 Feb 3;30(5):1657-76. doi: 10.1523/JNEUROSCI.3111-09.2010.
The transplantation of neural stem/progenitor cells (NPCs) is a promising therapeutic strategy for spinal cord injury (SCI). However, to date NPC transplantation has exhibited only limited success in the treatment of chronic SCI. Here, we show that chondroitin sulfate proteoglycans (CSPGs) in the glial scar around the site of chronic SCI negatively influence the long-term survival and integration of transplanted NPCs and their therapeutic potential for promoting functional repair and plasticity. We targeted CSPGs in the chronically injured spinal cord by sustained infusion of chondroitinase ABC (ChABC). One week later, the same rats were treated with transplants of NPCs and transient infusion of growth factors, EGF, bFGF, and PDGF-AA. We demonstrate that perturbing CSPGs dramatically optimizes NPC transplantation in chronic SCI. Engrafted NPCs successfully integrate and extensively migrate within the host spinal cord and principally differentiate into oligodendrocytes. Furthermore, this combined strategy promoted the axonal integrity and plasticity of the corticospinal tract and enhanced the plasticity of descending serotonergic pathways. These neuroanatomical changes were also associated with significantly improved neurobehavioral recovery after chronic SCI. Importantly, this strategy did not enhance the aberrant synaptic connectivity of pain afferents, nor did it exacerbate posttraumatic neuropathic pain. For the first time, we demonstrate key biological and functional benefits for the combined use of ChABC, growth factors, and NPCs to repair the chronically injured spinal cord. These findings could potentially bring us closer to the application of NPCs for patients suffering from chronic SCI or other conditions characterized by the formation of a glial scar.
神经干细胞/祖细胞(NPCs)的移植是脊髓损伤(SCI)的一种很有前途的治疗策略。然而,迄今为止,NPC 移植在治疗慢性 SCI 方面仅取得了有限的成功。在这里,我们表明,慢性 SCI 部位胶质瘢痕中的硫酸软骨素蛋白聚糖(CSPGs)会对移植 NPC 的长期存活和整合及其促进功能修复和可塑性的治疗潜力产生负面影响。我们通过持续输注软骨素酶 ABC(ChABC)来靶向慢性损伤脊髓中的 CSPGs。一周后,相同的大鼠接受 NPC 移植和生长因子 EGF、bFGF 和 PDGF-AA 的短暂输注治疗。我们证明,扰乱 CSPGs 可极大地优化慢性 SCI 中的 NPC 移植。植入的 NPC 成功整合并在宿主脊髓内广泛迁移,并主要分化为少突胶质细胞。此外,这种联合策略还促进了皮质脊髓束的轴突完整性和可塑性,并增强了下行 5-羟色胺能途径的可塑性。这些神经解剖学变化也与慢性 SCI 后神经行为恢复的显著改善相关。重要的是,这种策略不会增强疼痛传入纤维的异常突触连接,也不会加剧创伤后神经病理性疼痛。我们首次证明了 ChABC、生长因子和 NPC 联合使用修复慢性损伤脊髓的关键生物学和功能益处。这些发现可能使我们更接近将 NPC 应用于患有慢性 SCI 或其他以形成胶质瘢痕为特征的疾病的患者。
Stem Cell Res Ther. 2021-1-6
Int J Mol Sci. 2025-7-26
Neural Regen Res. 2026-4-1
Neural Regen Res. 2026-4-1
J Clin Med. 2024-7-13
Front Neurosci. 2024-6-26
Spine Surg Relat Res. 2023-9-4
J Neurosci. 2009-8-12
Brain Res Rev. 2008-1
J Neurosci. 2007-5-30